The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1395
July 23, 2012
View Complete Issue         Table of Contents 2019 
Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
July 23, 2012 (Issue: 1395)
Pertuzumab (Perjeta – Roche/Genentech), a humanized monoclonal antibody, has been approved by the FDA for use in combination with trastuzumab (Herceptin) and docetaxel (Taxotere, and others) for first-line treatment of human epidermal growth...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Article code: 1395c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.